litlas
ログインアカウント作成

Emilio Bajetta

1972–2025 年に発表

59
論文数
21,135
被引用数
56
h 指数
59
i10 指数

被引用数

Emilio Bajetta の年別被引用数1974 年: 被引用 1 件1975 年: 被引用 1 件1976 年: 被引用 3 件1977 年: 被引用 12 件1978 年: 被引用 8 件1979 年: 被引用 8 件1980 年: 被引用 8 件1981 年: 被引用 7 件1982 年: 被引用 4 件1983 年: 被引用 13 件1984 年: 被引用 2 件1985 年: 被引用 5 件1986 年: 被引用 6 件1987 年: 被引用 3 件1988 年: 被引用 4 件1989 年: 被引用 5 件1990 年: 被引用 8 件1991 年: 被引用 5 件1992 年: 被引用 6 件1993 年: 被引用 3 件1994 年: 被引用 5 件1995 年: 被引用 7 件1996 年: 被引用 8 件1997 年: 被引用 6 件1998 年: 被引用 14 件1999 年: 被引用 28 件2000 年: 被引用 45 件2001 年: 被引用 52 件2002 年: 被引用 74 件2003 年: 被引用 100 件2004 年: 被引用 131 件2005 年: 被引用 182 件2006 年: 被引用 162 件2007 年: 被引用 166 件2008 年: 被引用 203 件2009 年: 被引用 234 件2010 年: 被引用 276 件2011 年: 被引用 266 件2012 年: 被引用 185 件2013 年: 被引用 192 件2014 年: 被引用 148 件2015 年: 被引用 123 件2016 年: 被引用 136 件2017 年: 被引用 102 件2018 年: 被引用 104 件2019 年: 被引用 286 件2020 年: 被引用 264 件2021 年: 被引用 198 件2022 年: 被引用 125 件2023 年: 被引用 114 件2024 年: 被引用 174 件2025 年: 被引用 65 件2026 年: 被引用 2 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,707 件、この内訳の 26.2%イタリア: 引用元論文 548 件、この内訳の 8.4%イギリス: 引用元論文 506 件、この内訳の 7.7%フランス: 引用元論文 383 件、この内訳の 5.9%ドイツ: 引用元論文 365 件、この内訳の 5.6%中国: 引用元論文 307 件、この内訳の 4.7%カナダ: 引用元論文 255 件、この内訳の 3.9%オランダ: 引用元論文 215 件、この内訳の 3.3%スペイン: 引用元論文 212 件、この内訳の 3.2%スイス: 引用元論文 209 件、この内訳の 3.2%ベルギー: 引用元論文 200 件、この内訳の 3.1%日本: 引用元論文 176 件、この内訳の 2.7%
0%26.2%その他 22.1%

機関

分野

  • Medicine68.9%
  • Biochemistry, Genetics and Molecular Biology23%
  • Immunology and Microbiology4.8%
  • Materials Science0.5%
  • Mathematics0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他1.8%

トピック

  • Colorectal Cancer Treatments and Studies5.7%
  • Estrogen and related hormone effects3.6%
  • Breast Cancer Treatment Studies3.5%
  • Renal cell carcinoma treatment3.5%
  • Neuroendocrine Tumor Research Advances3.1%
  • Cancer Treatment and Pharmacology3%
  • その他77.6%

共著者

全論文

検索で開く
  1. Interleukin-12: Biological Properties and Clinical Application

    著者: Michele Del Vecchio, Emilio Bajetta, Stefania Canova, Michael T. Lotze, Amy Wesa, Giorgio Parmiani, Andrea Anichini - Clinical Cancer Research 2007 被引用: 604

  2. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    著者: Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J. Moore, David Cunningham, Thomas H. Cartwright, J. Randolph Hecht, Fernando Rivera, Seock‐Ah Im, G. Bodoky, Ramón Salazar, Frédérique Maindrault-Goebel, Einat Shacham‐Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M. Hoff - The Lancet Oncology 2012 被引用: 526

  3. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    著者: Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore - The Lancet 2007 被引用: 2,223

  4. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

    著者: Sara Pusceddu, Natalie Prinzi, Salvatore Tafuto, Toni Ibrahim, Angelina Filice, Maria Pia Brizzi, Francesco Panzuto, Sergio Baldari, Chiara Maria Grana, Davide Campana, Maria Vittoria Davì, Dario Giuffrida, Maria Chiara Zatelli, Stefano Partelli, Paola Razzore, Riccardo Marconcini, Sara Massironi, Fabio Gelsomino, Antongiulio Faggiano, Elisa Giannetta, Emilio Bajetta, Franco Grimaldi, Mauro Cives, Fernando Cirillo, Vittorio Perfetti, Francesca Corti, Claudio Ricci, Luca Giacomelli, Luca Porcu, Massimo Di Maïo, Ettore Seregni, Marco Maccauro, Secondo Lastoria, Alberto Bongiovanni, Annibale Versari, Irene Persano, Maria Rinzivillo, Salvatore Antonio Pignata, Paola Rocca, Giuseppe Lamberti, Sara Cingarlini, Ivana Puliafito, Maria Rosaria Ambrosio, Isabella Zanata, Alessandra Bracigliano, Stefano Severi, Francesca Spada, Valentina Andreasi, Roberta Modica, Federica Scalorbi, Massimo Milione, Giovanna Sabella, Jorgelina Coppa, Riccardo Casadei, Maria Di Bartolomeo, Massimo Falconi, Filippo de Braud - JAMA Network Open 2022 被引用: 59

  5. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

    著者: Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer, Christine Deutschmann, Stephanie Strobl, Miguel Martín, Jane Meisel, Nicholas Zdenkowski, Sibylle Loibl, Marija Balić, Haeseong Park, Aleix Prat, Claudine Isaacs, Emilio Bajetta, Justin M. Balko, Merixtell Bellet-Ezquerra, Judith M. Bliss, Harold J. Burstein, Fátima Cardoso, Hannes Fohler, Theodoros Foukakis, Karen A. Gelmon, Matthew P. Goetz, Tufia C. Haddad, Hiroji Iwata, Jacek Jassem, Soo Chin Lee, Barbro Linderholm, Maartje Los, Eleftherios P. Mamounas, Kathy D. Miller, Patrick G. Morris, Elisabetta Munzone, Einav Nili Gal‐Yam, Alistair Ring, Lois E. Shepherd, Christian F. Singer, Christoph Thomssen, Ling‐Ming Tseng, Pinuccia Valagussa, Eric P. Winer, Antonio C. Wolff, Gabriele Zoppoli, Jana Machacek‐Link, Céline Schurmans, Xin Huang, Eric Gauthier, Christian Fesl, Amylou C. Dueck, Angela DeMichele, Michael Gnant, on behalf of the PALLAS Groups and Investigators, David Cameron, Sarra El-Abed, Hope S. Rugo, Guenther G. Steger, Tiffany A. Traina, Gustavo Werutsky, Norman Wolmark - Journal of Clinical Oncology 2023 被引用: 34

  6. Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

    著者: Gianni Bonadonna, Ercole Brusamolino, Pinuccia Valagussa, Anna Rossi, Luisa Brugnatelli, Cristina Brambilla, Mario De Lena, Gabriele Tancini, Emilio Bajetta, R Musumeci, Umberto Veronesi - New England Journal of Medicine 1976 被引用: 1,334

  7. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

    著者: Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier - The Lancet 2009 被引用: 1,355

  8. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

    著者: Sara Pusceddu, Claudio Vernieri, Massimo Di Maïo, Riccardo Marconcini, Francesca Spada, Sara Massironi, Toni Ibrahim, Maria Pia Brizzi, Davide Campana, Antongiulio Faggiano, Dario Giuffrida, Maria Rinzivillo, Sara Cingarlini, Francesca Aroldi, Lorenzo Antonuzzo, Rossana Berardi, Laura Catena, Chiara De Divitiis, Paola Ermacora, Vittorio Perfetti, Annalisa Fontana, Paola Razzore, Carlo Carnaghi, Maria Vittoria Davì, Carolina Cauchi, Marilina Duro, Sergio Ricci, Nicola Fazio, Federica Cavalcoli, Alberto Bongiovanni, Anna La Salvia, Nicole Brighi, Annamaria Colao, Ivana Puliafito, Francesco Panzuto, Silvia Ortolani, Alberto Zaniboni, Francesco Di Costanzo, Mariangela Torniai, Emilio Bajetta, Salvatore Tafuto, Silvio Ken Garattini, Daniela Femia, Natalie Prinzi, Laura Concas, Giuseppe Lo Russo, Massimo Milione, Luca Giacomelli, Roberto Buzzoni, Gianfranco Delle Fave, Vincenzo Mazzaferro, Filippo de Braud - Gastroenterology 2018 被引用: 89

  9. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    著者: Eric Van Cutsem, Chris Twelves, Jim Cassidy, David Allman, Emilio Bajetta, Michael Boyer, R. Bugat, M Findlay, S. Frings, Michaela K. Jahn, Joe McKendrick, B Osterwalder, G. Pérez-Manga, Riccardo Rosso, Philippe Rougier, Wolff Schmiegel, Jean‐François Seitz, Paul Thompson, José María Viéitez, Christof Weitzel, Peter Harper - Journal of Clinical Oncology 2001 被引用: 1,036

  10. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

    著者: R. Charles Coombes, Emma Hall, Lorna J. Gibson, Robert Paridaens, Jacek Jassem, T. Delozier, Stephen E. Jones, Isabel Álvarez, Gianfilippo Bertelli, Olaf Ortmann, Alan S. Coates, Emilio Bajetta, David Dodwell, Robert E. Coleman, Lesley Fallowfield, E. Mickiewicz, Jørn Andersen, Per Eystein Lønning, Giorgio Cocconi, Alan L. Stewart, Nick Stuart, Claire Snowdon, M. Carpentieri, Giorgio Massimini, Judith M. Bliss - New England Journal of Medicine 2004 被引用: 1,767

  11. Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial

    著者: Michail Ignatiadis, Andrew Bailey, Heather L. McArthur, Sarra El-Abed, Evandro de Azambuja, Otto Metzger, Steve Chui, Max Dieterich, Thomas Perretti, Guenther G. Steger, Jacek Jassem, Soo Chin Lee, Michaela J. Higgins, José Zarbá, Marcus Schmidt, Henry Gómez, Ángel Guerrero‐Zotano, Luca Moscetti, Joanne Win Yang Chiu, Carter DuFrane, Vanessa Honvault, Rosa Altarcheh, Luciana Molinero, A. B. Ellingson, Elisabetta Munzone, Noa Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock‐Ah Im, Gustavo Werutsky, Einav Nili Gal‐Yam, Xavier González, Ling‐Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Ivan Sinielnikov, Zimina Anastasia, Aleksandr Vasiliev, E. Shearer-Kang, Eric S. Winer, Diogo Martins-Branco, Shona Fielding, David Cameron, Giuseppe Viale, Shigehira Saji, Richard D. Gelber, Martine Piccart - Cancer Research 2024 被引用: 13

  12. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

    著者: Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, N. Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, J. Wils, Lucile Awad, Patrice Herait, Christian Jacques - The Lancet 1998 被引用: 993

  13. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    著者: Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier, Emilio Bajetta, Bohuslav Melichar, Sergio Bracarda, Alain Ravaud, Sophie Golding, Sangeeta Jethwa, Vesna Šneller - Journal of Clinical Oncology 2010 被引用: 808

  14. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    著者: Richard Herrmann, G. Bodoky, Thomas Ruhstaller, Bengt Glimelius, Emilio Bajetta, Johannes Schüller, Piercarlo Saletti, Jean Bauer, Arié Figer, Bernhard C. Pestalozzi, Claus‐Henning Köhne, Walter Mingrone, Salomon M. Stemmer, Karin Rita Tamas, Gabriela Kornek, Dieter Koeberle, Susanne Cina, Jürg Bernhard, Daniel Dietrich, Werner Scheithauer - Journal of Clinical Oncology 2007 被引用: 591

  15. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

    著者: Jim Cassidy, Chris Twelves, Eric Van Cutsem, Paulo M. Hoff, Emilio Bajetta, Michael Boyer, R. Bugat, Ulrich Bürger, A. Garin, Ullrich Graeven, J. McKendrick, Jean A. Maroun, John L. Marshall, B Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, Richard L. Schilsky - Annals of Oncology 2002 被引用: 524

  16. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

    著者: Federica Perrone, Andrea Lampis, Marta Orsenigo, Maria Di Bartolomeo, Arpine Gevorgyan, Marco Losa, Milo Frattini, Catherine Riva, Salvatore Andreola, Emilio Bajetta, Lucio Bertario, Enrico Leo, Marco A. Pierotti, S. Pilotti - Annals of Oncology 2008 被引用: 414

  17. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

    著者: Emilio Bajetta, Laura Catena, Giuseppe Procopio, Sara De Dosso, E. Bichisao, Leonardo Ferrari, Antonia Martinetti, Marco Platania, Elena Verzoni, Barbara Formisano, Roberto Bajetta - Cancer Chemotherapy and Pharmacology 2006 被引用: 241

  18. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

    著者: Viviane Hess, Bengt Glimelius, Philipp Grawe, Daniel Dietrich, G. Bodoky, Thomas Ruhstaller, Emilio Bajetta, Piercarlo Saletti, Arié Figer, Werner Scheithauer, Richard Herrmann - The Lancet Oncology 2008 被引用: 238

  19. Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

    著者: Vera Hirsh, Luis Paz‐Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczęsna, Pavel Reiterer, Mansoor N. Saleh, Óscar Arrieta, Emilio Bajetta, R. Timothy Webb, Johannes Isaac Raats, Rebecca Benner, Camilla Fowst, Sandra J. Meech, David Readett, Joan H. Schiller - Journal of Clinical Oncology 2011 被引用: 139

  20. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

    著者: Michail Ignatiadis, Andrew Bailey, Heather L. McArthur, Sarra El-Abed, Evandro de Azambuja, Otto Metzger, Jane Yuet Ching Hui, Max Dieterich, Thomas Perretti, E. Shearer-Kang, Luciana Molinero, Günther Steger, Jacek Jassem, Soo Chin Lee, Michaela J. Higgins, Jose Zarba, Marcus Schmidt, Henry Gómez, Ángel Guerrero‐Zotano, Luca Moscetti, Joanne Chiu, Elisabetta Munzone, Noa Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock‐Ah Im, Gustavo Werutsky, Einav Nili Gal‐Yam, Xavier Farré, Ling‐Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric S. Winer, David Cameron, G. Viale, Shigehira Saji, Richard D. Gelber, Martine Piccart - JAMA 2025 被引用: 40

  21. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

    著者: Timothy J. Littlewood, Emilio Bajetta, J.W.R. Nortier, Els Vercammen, Bernardo L. Rapoport, for the Epoetin Alfa Study Group - Journal of Clinical Oncology 2001 被引用: 977

  22. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    著者: R. Charles Coombes, Lucy Kilburn, CF Snowdon, Robert Paridaens, RE Coleman, SE Jones, Jacek Jassem, CJH van de Velde, T. Delozier, Isabel Álvarez, Lucia Del Mastro, Olaf Ortmann, K. Diedrich, AS Coates, Emilio Bajetta, Holmberg Sb, David Dodwell, E. Mickiewicz, J. Andersen, Per Eystein Lønning, Giorgio Cocconi, John Forbes, M. Castiglione, N Stuart, A. Stewart, Lesley Fallowfield, Gianfilippo Bertelli, Emma Hall, Richard Bogle, M. Carpentieri, E Colajori, Milayna Subar, Elizabeth Ireland, Judith M. Bliss - The Lancet 2007 被引用: 909

  23. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

    著者: Maria Di Bartolomeo, Emilio Bajetta, Roberto Buzzoni, Luigi Mariani, Carlo Carnaghi, L. Somma, Nicoletta Zilembo, Angelo Di Leo - Cancer 1996 被引用: 296

  24. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors

    著者: Emilio Bajetta, Leonardo Ferrari, Antonia Martinetti, Luigi Celio, Giuseppe Procopio, Salvatore Artale, Nicoletta Zilembo, Maria Di Bartolomeo, Ettore Seregni, Emilio Bombardieri - Cancer 1999 被引用: 289